Associations of ABCB1 and XPC Genetic Polymorphisms with Susceptibility to Colorectal Cancer and Therapeutic Prognosis in a Chinese Population

  • Yue, Ai-Min (Oncological Surgery Department of Xinxiang Central Hospital) ;
  • Xie, Zhen-Bin (Oncological Surgery Department of Xinxiang Central Hospital) ;
  • Zhao, Hong-Feng (Oncological Surgery Department of Xinxiang Central Hospital) ;
  • Guo, Shu-Ping (Oncological Surgery Department of Xinxiang Central Hospital) ;
  • Shen, Yu-Hou (Oncological Surgery Department of Xinxiang Central Hospital) ;
  • Wang, Hai-Pu (Oncological Surgery Department of Xinxiang Central Hospital)
  • Published : 2013.05.30


Associations between ABCB1 and XPC genetic polymorphisms and risk of developing colorectal cancer (CRC) as well as clinical outcomes in CRCs with chemotherapy were investigated. A case-control study was performed on the ABCB1 C3435T, G2677T/A and XPC Lys939Gln polymorphisms in 428 CRC cases and 450 hospitalbased, age and sex frequency-matched controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays. We observed that the ABCB1 3435CT or CC+CT variants were significantly linked with increasing risk of developing CRC (adjusted OR (95% CI): 1.814 (1.237-2.660), P=0.0022; adjusted OR (95% CI): 1.605 (1.117-2.306), P=0.0102, respectively). Moreover, the distribution frequency of XPC AC genotype or AC+CC genotypes also showed a tendency towards increasing the suscepbility for CRC (P=0.0759 and P=0.0903, respectively). Kaplan-Meier curves showed that the ABCB1 C3435T variant was associated with a tendency toward longer progression-free survival (PFS) (n=343, Log-rank test: P=0.063), and the G2677T/A variant genotypes (GT+TT+GA+AA) with a tendency for longer OS in postoperative oxaliplatin-based patients (n=343, Log-rank test: P=0.082). However, no correlation of the XPC Lys939Gln polymorphism was found with PFS and OS in patients with postoperative oxaliplatin-based chemotherapy (n=343). Our study indicated that ABCB1 polymorphisms might be candidate pharmacogenomic factors for the prediction of CRC susceptibility, but not for prognosis with oxaliplatin chemosensitivity in CRC patients.


  1. Andersen V, Ostergaard M, Christensen J, et al (2009). Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer, 9, 407.
  2. Bae SY, Choi SK, Kim KR, et al (2006). Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci, 97, 774-9.
  3. De Iudicibus S, De Pellegrin A, Stocco G, et al (2008). ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res, 28, 3921-8.
  4. Engin AB, Karahalil B, Engin A, et al (2010). Oxidative stress, Helicobacter pylori, and OGG1 Ser326Cys, XPC Lys939Gln, and XPD Lys751Gln polymorphisms in a Turkish population with colorectal carcinoma. Genet Test Mol Biomarkers, 14, 559-64.
  5. Ferguson LR, De Flora S (2005). Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutation Research, 591, 24-33.
  6. Fromm MF (2002). The influence of MDR1 polymorphisms on p-glycoprotein expression and function in humans. Adv Drug Deliv Rev, 54, 1295-310.
  7. Friedberg EC (2001). How nucleotide excision repair protects against cancer. Nat Rev Cancer, 1, 22-33.
  8. Gervasini G, Carrillo JA, Garcia M, et al (2006). Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer, 107, 2850-7.
  9. Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews, Cancer, 2, 48-58.
  10. Hansen RD, Sorensen M, Tjonneland A, et al (2007). XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer.Mutat Res, 619, 68-80.
  11. Janicijevic A, Sugasawa K, Shimizu Y, et al (2003). DNA bending by the human damage recognition complex XPCHR23B. DNA Repair (Amst), 2, 325-36.
  12. Kang S, Sun HY, Zhou RM, et al (2013). DNA Repair Gene Associated with Clinical Outcome of Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy. Asian Pac J Cancer Prev, 14, 941-6.
  13. Kerb R (2006). Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Letters, 234, 4-33.
  14. Khedri A, Nejat-Shokouhi A, Salek R, et al (2011). Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep, 38, 2939-43.
  15. Kim, RB, Leake, BF, Choo, EF, et al (2001).Identification of functionally variant MDR1 alleles among EuropeanAmericans and African Americans. Clin Pharmacol Ther, 70, 189-99.
  16. Kusumoto R, Masutani C, Sugasawa K, et al (2001). Diversity of the damage recognition step in the global genomic nucleotide excision repair in vitro. Mutat Res, 485, 219-27.
  17. Leonessa F, Clarke R (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer, 10, 43-73.
  18. Leschziner GD, Andrew T, Pirmohamed M, et al (2007). ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. The Pharmacogenomics Journal, 7, 154-79.
  19. Liu D,Wu HZ, Zhang YN, et al (2012). DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog, 51, E83-93.
  20. Nishi R, Okuda Y, Watanabe E, et al (2005). Centrin 2 stimulates nucleotide excision repair by interacting with xeroderma pigmentosum group C protein. Mol Cell Biol, 25, 5664-74.
  21. Pourhoseingholi MA (2012). Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol, 4, 68-70.
  22. Robert J, Morvan VL, Smith D, et al (2005). Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol, 54, 171-96.
  23. Samanian S,Mahjoubi F,Mahjoubi B, et al (2011). MDR1 gene polymorphisms: possible association with its expression and clinicopathology characteristics in colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3141-45.
  24. Sugasawa K, Shimizu Y, Iwai S, et al (2002). A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair (Amst), 1, 95-107.
  25. Wu Y, Jin M, Liu B, et al (2011). The association of XPC polymorphisms and tea drinking with colorectal cancer risk in a Chinese population. Mol Carcinog, 50, 189-98.

Cited by

  1. Maternal Medication Use, Fetal 3435 C>T Polymorphism of the ABCB1 Gene, and Risk of Isolated Septal Defects in a Han Chinese Population vol.35, pp.7, 2014,
  2. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients vol.17, pp.7, 2016,
  3. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy vol.233, pp.3, 2017,
  4. Association of XPC Gene Polymorphisms with Colorectal Cancer Risk in a Southern Chinese Population: A Case-Control Study and Meta-Analysis vol.7, pp.10, 2016,
  5. Association between MDR1 C3435T polymorphism and colorectal cancer risk vol.96, pp.51, 2017,
  6. Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS) vol.18, pp.5, 2018,